Protein Polymer Technologies, Inc. (OTC BB: PPTI) today announced that it has been notified by Spine Wave, Inc., that approval for an Investigational Device Exemption has been received from the U.S. Food and Drug Administration (FDA). This allows Spine Wave to conduct a pilot human clinical trial to investigate the safety and effectiveness of the company's NuCore™ Injectable Nucleus.
